演題詳細

一般口演 / Oral Session

【E】一般口演 16 (Oral Session 16) :MDS:Clinical Research 3

print

日程
2013年10月11日(金)
時間
10:00 - 11:30
会場
第14会場 / Room No.14 (札幌市教育文化会館 3F 研修室305)
座長・司会
石川 隆之 (Takayuki Ishikawa):1
1:Department of Hematology, Kobe City Medical Center General Hospital, Japan
 
前へ戻る

Serum microRNA-21 as a potent biomarker for response to hypomethylating agents in myelodysplastic syndromes

演題番号 : OS-1-79

June-Won Cheong (丁 晙元):1、Yundeok Kim:1、Yeo-Kyeoung Kim:2、Ju-In Eom:3、Hoi-Kyung Jeung:1、Soo Jeong Kim:1、Dohyu Hwang:1、Jin Seok Kim:1、Hyeuong Joon Kim:2、Yoo Hong Min:1

1:Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea、2:Department of Internal Medicine, Chonnam National University Hwasun Hospital, Jeonnam, Korea、3:Medical Research Center, Yonsei University College of Medicine, Seoul, Korea

 

[Background] Sensitive biomarkers predicting response to hypomethylating agents (HMA) is necessary to establish optimized strategies for epigenetic therapy in myelodysplastic syndromes (MDS). [Design and Methods] Serum miR-21 was quantitatively measured in 58 MDS patients treated with HMA and 14 healthy controls. Serum miR-192 was an internal control, and diagnostic performance was evaluated using the receiver operating characteristics (ROC). [Results] ROC analysis indicated serum miR-21 was useful in differentiating responder from non-responder with AUC of 0.648 (95% CI, 0.49 to 0.72). The baseline level of serum miR-21 was significantly lower in the responder group than in the non-responder group (P=0.041). Overall response rate (ORR) in the high miR-21 group was significantly lower than that in the low group (41.2 vs 73.2%, P=0.021). Progression-free survival (PFS) was significantly inferior in the high group than in the low group (14.0 vs. 44.5 months, P=0.001). Multivariate analyses revealed initial serum miR-21 level (P=0.001) and circulating blasts (P=0.007) remained as prognostic factors for PFS. [Conclusion] Serum miR-21 level was significantly associated with ORR and PFS in MDS patients treated with HMA. Although validation with large prospective study is required, serum miR-21 can be a potential biomarker in designing risk-adaptive epigenetic therapy for MDS patients.

前へ戻る